Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial

Nguyen Q.; Merrill P.; Jaffe G.; Dick A.; Kurup Shree K.; Sheppard J.; Schlaen Ariel; Pavesio C.; Cimino L.; Calster Joachim Van; Camez A.; Kwatra N.; Song A.; Kron M.; Tari S.; Brézin A.

doi:10.1016/s0140-6736(16)31339-3

← Today's brief

L2 StudyUnblinded

Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial

Nguyen Q. et al. · Lancet · Friday, January 1, 2016

Read original

Design Level 2n 114Funding Not reported

The one catch: Unblinded, so outcome assessment may be swayed by knowing the assignment.

Source

Nguyen Q. et al.. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. Friday, January 1, 2016.
doi:10.1016/s0140-6736(16)31339-3

Generated, then checked claim-by-claim against the source · how this brief was built →

Physician-designed methodology · Amr Saad, MD MBA

Sign in to rate and bookmark articles

Automated evidence summary, checked against the source. Not medical advice. Verify with the original publication.